Recombinant ADAR antibody

Catalog No. ABIN7127324

Product Details anti-ADAR Antibody

Target: ADAR (Adenosine Deaminase, RNA-Specific (ADAR))

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Rabbit

Clonality: Monoclonal

Conjugate: This ADAR antibody is un-conjugated

Application: Immunohistochemistry (IHC), ELISA

Cross-Reactivity: Human

Purification: Affinity-chromatography

Immunogen: A synthesized peptide derived from human ADAR1

Clone: 7H12

Isotype: IgG

Application Details

Application Notes: Recommended dilution: IHC:1:50-1:200,

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Rabbit IgG in phosphate buffered saline, pH 7.4, 150 mM NaCl, 0.02 % sodium azide and 50 % glycerol.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Target Details for ADAR

Target: ADAR (Adenosine Deaminase, RNA-Specific (ADAR))

Alternative Name: ADAR (ADAR Products)

Synonyms: red1 antibody, drada antibody, wu:fc22a02 antibody, adar1 antibody, dsRAD antibody, dsRAD-1 antibody, ADAR antibody, ADAR1 antibody, CG12598 antibody, Dmel\\CG12598 antibody, EG:BACN35H14.1 antibody, adar antibody, adr antibody, cg12598 antibody, dADAR antibody, dAdar antibody, hypnos-2 antibody, NV18763 antibody, AGS6 antibody, DRADA antibody, DSH antibody, DSRAD antibody, G1P1 antibody, IFI-4 antibody, IFI4 antibody, K88DSRBP antibody, P136 antibody, AV242451 antibody, Adar1 antibody, mZaADAR antibody, adenosine deaminase, RNA-specific antibody, adenosine deaminase, RNA-specific S homeolog antibody, adenosine deaminase, RNA specific antibody, Adenosine deaminase acting on RNA antibody, adenosine deaminase acting on RNA antibody, double-stranded RNA-specific editase 1 antibody, adar antibody, adar.S antibody, ADAR antibody, Adar antibody, CpipJ_CPIJ011849 antibody, LOC100114127 antibody

Background:

Background: Catalyzes the hydrolytic deamination of adenosine to inosine in double-stranded RNA (dsRNA) referred to as A-to-I RNA editing. This may affect gene expression and function in a number of ways that include mRNA translation by changing codons and hence the amino acid sequence of proteins, pre-mRNA splicing by altering splice site recognition sequences, RNA stability by changing sequences involved in nuclease recognition, genetic stability in the case of RNA virus genomes by changing sequences during viral RNA replication, and RNA structure-dependent activities such as microRNA production or targeting or protein-RNA interactions. Can edit both viral and cellular RNAs and can edit RNAs at multiple sites (hyper-editing) or at specific sites (site-specific editing). Its cellular RNA substrates include: bladder cancer-associated protein (BLCAP), neurotransmitter receptors for glutamate (GRIA2) and serotonin (HTR2C) and GABA receptor (GABRA3). Site-specific RNA editing of transcripts encoding these proteins results in amino acid substitutions which consequently alters their functional activities. Exhibits low-level editing at the GRIA2 Q/R site, but edits efficiently at the R/G site and HOTSPOT1. Its viral RNA substrates include: hepatitis C virus (HCV), vesicular stomatitis virus (VSV), measles virus (MV), hepatitis delta virus (HDV), and human immunodeficiency virus type 1 (HIV-1). Exhibits either a proviral (HDV, MV, VSV and HIV-1) or an antiviral effect (HCV) and this can be editing-dependent (HDV and HCV), editing-independent (VSV and MV) or both (HIV-1). Impairs HCV replication via RNA editing at multiple sites. Enhances the replication of MV, VSV and HIV-1 through an editing-independent mechanism via suppression of EIF2AK2/PKR activation and function. Stimulates both the release and infectivity of HIV-1 viral particles by an editing-dependent mechanism where it associates with viral RNAs and edits adenosines in the 5'UTR and the Rev and Tat coding sequence. Can enhance viral replication of HDV via A-to-I editing at a site designated as amber/W, thereby changing an UAG amber stop codon to an UIG tryptophan (W) codon that permits synthesis of the large delta antigen (L-HDAg) which has a key role in the assembly of viral particles. However, high levels of ADAR1 inhibit HDV replication.

Aliases: Double-stranded RNA-specific adenosine deaminase (DRADA) (EC 3.5.4.37) (136 kDa double-stranded RNA-binding protein) (p136) (Interferon-inducible protein 4) (IFI-4) (K88DSRBP), ADAR, ADAR1 DSRAD G1P1 IFI4

UniProt: P55265

Pathways: Protein targeting to Nucleus